NCT07220187View on ClinicalTrials.gov

Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID Trial

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

May 2, 2026

Primary Completion Date

October 1, 2035

Study Completion Date

October 31, 2036

Conditions
Richter SyndromeTransformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell LymphomaTransformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood and buccal swab sample collection

PROCEDURE

Computed Tomography

Undergo CT scan and/or PET/CT scan

DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

PROCEDURE

Echocardiography Test

Undergo echocardiography

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA scan

DRUG

Pirtobrutinib

Given PO

PROCEDURE

Positron Emission Tomography

Undergo PET/CT scan

DRUG

Prednisone

Given PO

BIOLOGICAL

Rituximab

Given IV

BIOLOGICAL

Rituximab and Hyaluronidase Human

Given SC

OTHER

Survey Administration

Ancillary studies

DRUG

Vincristine

Given IV

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

SWOG Cancer Research Network

NETWORK